NWBO

Northwest Biotherapeutics, Inc. [NWBO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NWBO Stock Summary

Top 10 Correlated ETFs

NWBO

Top 10 Correlated Stocks

NWBO

In the News

NWBO Financial details

Company Rating
-
Market Cap
618.78M
Income
-62.23M
Revenue
1.93M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
25
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-9.15
Forward P/E
-
PEG
1.59
P/S
359.78
P/B
-11.32
P/C
-
P/FCF
-14.79
Quick Ratio
0.14
Current Ratio
0.17
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.99%
Revenue last 5Y
-4.33%
Revenue Q/Q
9.61%
EPS Q/Q
-2.38%
-
-
-
-
SMA20
-7.69%
SMA50
-11.11%
SMA100
-14.29%
Inst Own
-
Inst Trans
-
ROA
-256%
ROE
104%
ROC
3.3%
Gross Margin
100%
Oper. Margin
-2809%
Profit Margin
-3865%
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.4-1.09
52W High
-
52W Low
-
RSI
42.93
Rel Volume
1.41
Avg Volume
1.79M
Volume
2.52M
Perf Week
-1.06%
Perf Month
-4.36%
Perf Quarter
-23.27%
Perf Half Y
-27.89%
-
-
-
-
Beta
-0.698
-
-
Volatility
0.01%, 0.01%
Prev Close
-2.33%
Price
0.23442
Change
1.48%

Something similar

Top by Market Cap
GOOG
LLY.SW
BRH.DE
NVD.DE
APC.DE
Top Correlated ETFs
VUTY.L
VEMT.L
TRXG.L
MUNS.L
TRSG.L
Top Correlated Stocks
ARLO
IOM.L
FPAR-A.ST
0RQO.L
RILYL
Similar Market Cap
SAVE
0606.HK
ABINX
IMCV
SVM

Company Profile

Healthcare Biotechnology
  • Volume Average 1.79M
  • Market Capitalization 618.78M
  • Employee 25
  • CEO Ms. Linda F. Powers J.D.
  • Headquarters Bethesda,MD,US
  • IPO Date 2001-12-14
  • Website https://www.nwbio.com

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.